Skip to content

Medical emergency? What to do

Early close of trial of treatment for peripheral arterial disease announced

3-RXPublished October 3, 20052 min read

Key points

  • (VSGN), focused on the development of immune modulation therapies for the treatment of cardiovascular disease, announced the early close out of the 550-patient, double-blind, placebo-controlled Phase 3 SIMPADICO trial of its Celacade technology for the treatment of symptomatic peripheral arterial disease (PAD).
  • The Steering Committee's recommendation was based on a recommendation by the trial's External Safety and Efficacy Monitoring Committee (ESEMC).
  • The SIMPADICO trial enrolled 553 patients with moderate to severe PAD at 50 centers throughout North America.
  • Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease.

Vasogen Inc. (VSGN), focused on the development of immune modulation therapies for the treatment of cardiovascular disease, announced the early close out of the 550-patient, double-blind, placebo-controlled Phase 3 SIMPADICO trial of its Celacade technology for the treatment of symptomatic peripheral arterial disease (PAD).

The decision to close out the trial at this time is based on a recommendation received from the SIMPADICO Steering Committee.

The Steering Committee's recommendation was based on a recommendation by the trial's External Safety and Efficacy Monitoring Committee (ESEMC). The ESEMC recommended the early close out of the study based on the absence of a sufficiently strong efficacy signal and their observation of a modest imbalance in the distribution of a small number of malignancy cases.

Based on the steering committee's own review and the findings of an independent expert in medical oncology, the steering committee concluded that no safety concern existed. However, given that the ESEMC's analysis also incorporated efficacy information and all patients have completed the assessments necessary for the analysis of the primary endpoint, the steering committee recommended the early close out of the trial.

The SIMPADICO trial enrolled 553 patients with moderate to severe PAD at 50 centers throughout North America. The study population was predominantly male (72%), Caucasian (89%), current or ex-smokers (91%), with a mean age of 67 years. The primary endpoint in SIMPADICO is the change in maximal walking distance after 6 months' treatment; a primary efficacy endpoint recognized by the U.S. Food and Drug Administration (FDA) and other regulatory authorities for approving new treatments for symptomatic PAD.

Clinical assessments of the 6-month primary endpoint were completed in July of this year and the majority of patients in the study have completed an additional 6 months of therapy as outlined in the study protocol.

Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease.

2005, NewsRx.com.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underHeart

Keep reading

Heart

Early sexual abuse increases heart risks

Women who were repeatedly sexually abused as girls have a 62 percent higher risk of heart problems later in life compared with women who were not abused, U.S. researchers said on Sunday. The findings, presented at…

2 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.